A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and
biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind,
placebo-controlled part A, followed by an open-label part B.